Reduxin
| LS-002110 | |
| Name | Reduxin |
| Dosage form | Capsule |
| Nosological classification | A08A Antiobesity preparations (excluding diet products) |
| Active agent | Sibutramine hydrochloride monohydrate – 10 mg Microcrystalline cellulose – 158.5 mg |
The quality, efficacy and safety of Redexin, time-tested and confirmed by the results achieved, allow it to be considered as a reference2 body weight loss product. It helps people get rid of extra kilograms and improve their health for more than 15 years. Hundreds of studies, thousands of professionals and millions of grateful people are behind this invaluable experience. It has been proven that weight loss resulted from the use of Reduxin reduces the risk of developing diabetes mellitus and cancer, increases the chances of conceiving and giving birth to a healthy child, protects the heart and prolongs active life.
Reduxin is effective for weight loss regardless of gender, age and comorbidities thanks to its activities in 3 directions:
1. It increases the level of endogenous serotonin, the hormone of happiness.
A person ceases to be dependent on food, hunger and craving for fatty and sweet decrease, and the feeling of saturation increases. Food portions became smaller and weight is lost, a person learns to eat correctly.
2. Reduxin activates fat breakdown and increases internal energy consumption, which further increases the efficiency of weight loss.
3. It helps to develop adequate eating habits, which further helps to maintain the achieved results.
Reduxin is indicated:
For overweight people to rationally reduce and maintain body weight, develop proper eating habits, and maintain healthy lifestyles.*
How to use: **
Reduxin is convenient and easy to use: only 1 tablet per day continuously up to 1 year.
Dry mouth and feeling of thirst during treatment means that the active process of breakdown of adipose tissue and weight loss has begun; adequate drinking regime is recommended.
Notes:
Do not use in children and pregnant women.
Sources:
* According to the prescribing information (LP-005315-231219, amendment No. 3, LP-005315, 2021). Body weight correction and improvement of lipid and carbohydrate metabolism in patients with a BMI of 27 kg/m2 or more, with concomitant type 2 diabetes mellitus and dyslipidemia.
** Prescription product. Consult a doctor before use.
According to Proxima, AlphaRM, 2022.
Rubricator of clinical recommendations (minzdrav.gov.ru), slovaronline.com.
